Novartis Broadens VISION On Radioligands

Firm Prepares For Expansion Into Prostate Cancer

 
• By Mary Jo Laffler

Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge. 

Binocular viewer_1200X675
Novartis is looking ahead to new horizons for 177Lu-PSMA-617

More from ASCO

More from Conferences